



Current Strategies for Cell-Based Cardiac Therapies

Guest Editors:

Dr. Jan W. Buikema

Amsterdam Cardiovascular
Sciences, Department of
Physiology, Amsterdam
University Medical Centers, De
Boelelaan 1108, 1081 HZ
Amsterdam, The Netherlands

Dr. William Rowland Goodyer

1. Cardiovascular Institute,
Stanford University School of
Medicine, Stanford, CA 94305,
USA
2. Department of Pediatrics,
Stanford University, Stanford, CA
94305, USA

Deadline for manuscript
submissions:

closed (31 October 2023)

Message from the Guest Editors

Dear Colleagues,

Cardiac injury, including blunt cardiac injury and penetrating cardiac injury, can result in a variety of specific injuries to the heart, the most common of which is myocardial contusion, a bruise (contusion) to the heart after an injury. Other potential injuries include septal defects and valvular failures, and the right ventricle is thought to be most commonly affected.

Autologous tissue therapy means that are removed from, and applied to, the same person, i.e., the donor and the recipient, are the same. The holy grail in translational cardiology is the repair of cardiac injury with autologous tissue or locally regenerate damaged myocardium or conduction systems. Autologous cell-based cardiac therapies have emerged as among the most promising strategies for treating heart injury. This Special Issue will be dedicated to novel technologies in mammalian cardiac cell-subtype generation and integration and explore strategies for local regeneration of the heart myocardium or conduction system.

Dr. Jan W. Buikema
Dr. William Rowland Goodyer
Guest Editors

